Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · IEX Real-Time Price · USD
1.780
+0.050 (2.89%)
Jul 22, 2024, 10:25 AM EDT - Market open
Palatin Technologies Employees
Palatin Technologies had 34 employees as of June 30, 2023. The number of employees increased by 1 or 3.03% compared to the previous year.
Employees
34
Change (1Y)
1
Growth (1Y)
3.03%
Revenue / Employee
$173,589
Profits / Employee
-$967,134
Market Cap
28.72M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Renalytix | 102 |
Bolt Biotherapeutics | 100 |
Enlivex Therapeutics | 71 |
Surrozen | 42 |
Acasti Pharma | 32 |
Brainstorm Cell Therapeutics | 29 |
bioAffinity Technologies | 14 |
Akari Therapeutics, | 12 |
PTN News
- 4 weeks ago - Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds - PRNewsWire
- 4 weeks ago - Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) - PRNewsWire
- 5 weeks ago - Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity - PRNewsWire
- 2 months ago - Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 - PRNewsWire
- 2 months ago - Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity - PRNewsWire
- 2 months ago - Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 - PRNewsWire
- 3 months ago - Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 - PRNewsWire